PDS Biotechnology Corporation (PDSB) News
Filter PDSB News Items
PDSB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PDSB News From Around the Web
Below are the latest news stories about PDS BIOTECHNOLOGY CORP that investors may wish to consider to help them evaluate PDSB as an investment opportunity.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment |
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ETDiscussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiationPRINCETON, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) event to discu |
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a TurnaroundThe heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...PDS Biotechnology Corp (PDSB) reports a solid cash position amid increased R&D expenses and promising clinical trial updates. |
PDS Biotechnology: Q3 Earnings SnapshotEAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Thursday reported a loss of $10.7 million in its third quarter. The East Princeton, New Jersey-based company said it had a loss of 29 cents per share. The results matched Wall Street expectations. |
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial ResultsConference call and webcast today at 8:30 a.m. Eastern TimePRINCETON, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the third quarter of 2024. “Since our last update in August, we have been actively e |
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern TimePRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a. |
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should KnowPDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an ImmunocytokineStudy to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute at Cytokines 2024PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the rationale and trial design for a st |
Best Momentum Stocks to Buy for October 15thORLA, BABA and PDSB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 15, 2024. |